Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2022, which reflect robust in-line product growth, increased adoption of new product portfolio and strong commercial execution. “We continue to execute against our strategic priorities, deliver solid revenue and earnings growth and advance our product pipeline,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “Thanks to our team's hard work and de

Bristol Myers Squibb Reports First Quarter Financial Results for 2022

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Camzyos (mavacamten)

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

AbbVie

AstraZeneca

Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bristol-Myers (BMY) Might Surprise This Earnings Season

BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.

What To Expect From Bristol Myers Squibb Stock After Q1 Results?

Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.

Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?

Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S.

Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb

Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.  Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his.

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

Kroger

Occidental Petroleum

They aren't the most exciting stocks out there, but these long-term winners have what they need to keep climbing.

3 Soaring Warren Buffett Stocks You Can Buy for $76 or Less

Chevron

They're not good picks just because of their dividends.

3 Warren Buffett Dividend Stocks You Can Buy Right Now

Huntington Bancshares

NextEra Energy

Dividend investors may be interested in the following stocks as they offer much higher dividend yields than the S&P 500 Index. The U.S. benchmark index returned 1.45% at the end of regular hours on Friday.

3 High-Yield Stocks for Dividend Investors

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, today announced an $80 million Series B financing round led by Catalio Capital Management (“Catalio”), established a Deep Mutational Scanning (“DMS”) biopharma partnership with Bristol Myers Squibb, and appointed biotech industry veteran Dean “Rick” Artis as its first Ch

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Veeva Systems

Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed Modernization streamlines trial management to speed medicines to patients PLEASANTON, Calif. , April 21, 2022 /PRNewswire/ -- Veeva Systems today announced that Bristol Myers Squibb has implemented Veeva Vault CTMS globally to drive end-to-end trial management.

Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally

Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes

EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park

Suncor Energy

The Oracle of Omaha especially likes one of these big winners.

4 Warren Buffett Stocks That Are Absolutely Trouncing the Market

BMY has rallied since late November 2021, from $53 to $77 currently, and one can question whether the shares still represent good value or may already be overvalued. The company's current portfolio generates ample free cash flow, the pipeline is very strong, and management is very confident about BMY's prospects.

Bristol Myers Squibb - AbbVie 2.0?

Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb's BMY, -1.20% Opdivo. The combination was being tested in several types of cancer, including renal cell carcinoma and urothelial carcinoma.

Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.  The decision follows the results from pre-planned analyses of two late-.

Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program

PRINCETON, N.J. and SAN FRANCISCO , April 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb  (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)

Amylyx Pharmaceuticals

Biogen

bluebird bio

Gilead Sciences

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

5 Key FDA Decisions Could Affect Drug Stocks

Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.

Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC

Vertex Pharmaceuticals

All three are near 52-week highs, but for how long?

3 Soaring Pharma Stocks -- Can They Keep Climbing?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR--Neoadjuvant Opdivo with Chemo Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Foundation Honors Diversity & Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences

Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter

News for Bristol-Myers Stock (BMY)